Zelenectide pevedotin
Phase 2Small molecule
Zelenectide pevedotin is one of 99 small molecule programs targeting Solid Tumor. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
98
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lexiscan
AstellasPreclinical
Zelenectide pevedotin
BBicycleTx Limited
Phase 2
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tianeptine
PfizerPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zelenectide pevedotin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBicycleTx Limited